What is CJC-1295 No DAC?

CJC-1295 No DAC is a synthetic 29-amino-acid growth hormone-releasing hormone analogue. It is also commonly referred to as Modified GRF 1-29 or Mod GRF.

Unlike CJC-1295 DAC, the No DAC version is shorter acting and is usually discussed for supporting a more pulsatile growth hormone release pattern. In research discussions, it is commonly associated with GH and IGF-1 signalling, recovery, sleep quality, body composition, lean mass and metabolic function.

CJC-1295 No DAC Reconstitution Example

The example below is based on a common 5mg CJC-1295 No DAC vial mixed with 3.0mL bacteriostatic water.

Standard / Gradual Research Protocol Example

This example uses a 5mg vial reconstituted with 3.0mL bacteriostatic water, giving an approximate concentration of 1.67mg/mL.

Frequency and Timing Notes

CJC-1295 No DAC is commonly discussed as a once-daily subcutaneous compound in research-style protocols. Because it is shorter acting than the DAC version, timing is usually more frequent and often positioned around natural growth hormone pulses.

Bedtime timing is commonly discussed because natural growth hormone release tends to be strongest during deep sleep. Some guides also suggest using it in a fasted state, often at least 2 hours away from food, to support the desired GH response.

For smaller measurements around 10 units or less, a 30-unit or 50-unit insulin syringe may be easier to read than a larger 1mL syringe.

Reconstitution Steps

1. Confirm the vial size before calculating concentration.
2. Draw 3.0mL bacteriostatic water using sterile technique.
3. Inject the bacteriostatic water slowly down the inside wall of the vial.
4. Avoid blasting the powder directly and avoid creating foam.
5. Gently swirl or roll the vial until the powder is fully dissolved.
6. Do not shake aggressively.
7. Label the vial with the reconstitution date.
8. Store the reconstituted vial in the refrigerator at 2-8°C, protected from light.

Supplies Needed

The following example is based on an 8-16 week daily research-style schedule using 5mg CJC-1295 No DAC vials.

Protocol Overview

• Goal discussed in research: stimulate pulsatile growth hormone release and elevate IGF-1 levels.
• Schedule example: daily subcutaneous use for 8-12 weeks, with some examples extending to 16 weeks.
• Example amount range: 100-300mcg daily using gradual titration.
• Example reconstitution: 3.0mL bacteriostatic water per 5mg vial.
• Concentration: approximately 1.67mg/mL.
• Timing: commonly discussed at bedtime to align with nocturnal GH pulses.
• Storage: lyophilised vials refrigerated or frozen, reconstituted vials refrigerated.

Example Dosing Protocol

• Start: 100-150mcg daily.
• Progression: increase by around 50mcg every 1-2 weeks as tolerated in research-style examples.
• Target example: 200-300mcg daily by weeks 5-12.
• Frequency: once daily in this example.
• Cycle length: 8-12 weeks, with optional extension to 16 weeks in some protocols.
• Timing: bedtime timing is commonly discussed, with site rotation.
• Fasted note: some protocols discuss administering away from food to support GH response.

How CJC-1295 No DAC Works

CJC-1295 No DAC, also known as Modified GRF 1-29, is a modified GHRH analogue designed to stimulate the pituitary gland to release endogenous growth hormone.

The No DAC version is shorter acting than CJC-1295 DAC. It is often discussed as having a short half-life, producing more discrete growth hormone pulses rather than the longer sustained exposure associated with DAC.

Research discussions often describe CJC-1295 No DAC as supporting GH and IGF-1 levels while preserving the body’s natural feedback loop and pulsatile release pattern.

Potential Benefits Discussed in Research

• Pulsatile growth hormone release
• IGF-1 elevation with repeated administration
• Body composition research
• Lean mass support pathways
• Reduced fat mass research models
• Recovery and energy discussions
• Sleep quality and nocturnal GH pulse support
• Metabolic function research

Reported Side Effects and Limitations

CJC-1295 No DAC is generally discussed as well tolerated in research-style guides, but side effects may still occur, especially during titration.

• Mild injection-site redness
• Swelling or irritation around the injection site
• Transient flushing
• Headache
• Water retention in some GH-axis discussions
• Possible changes related to GH and IGF-1 elevation
• Unknown long-term outcomes outside studied settings

Storage Instructions

• Lyophilised powder: store refrigerated at 2-8°C, or freeze at ≤-20°C for longer storage if directed by the supplier.
• After reconstitution: refrigerate at 2-8°C.
• Use window: commonly discussed as 1-2 weeks after reconstitution.
• Avoid: heat, sunlight, repeated freeze-thaw cycles and leaving the vial at room temperature for extended periods.
• Practical note: allow cold vials to reach room temperature before opening to reduce condensation exposure.

Injection Technique Notes

This section is general educational information only. It is not personal injection instruction.

• Use a new sterile insulin syringe for each administration.
• Clean the vial stopper and skin with alcohol and allow to dry.
• Common subcutaneous sites discussed include abdomen, thighs and upper arms.
• Rotate injection sites to reduce local irritation.
• Pinch a skinfold and insert into subcutaneous tissue at an appropriate angle.
• Do not aspirate for subcutaneous injections.
• Inject slowly and steadily.
• Wait a few seconds before withdrawing the needle.
• Dispose of used sharps safely in a sharps container.

Lifestyle Factors That May Matter

• Protein-forward diet: supports recovery and body composition goals.
• Resistance training: may complement GH-axis and lean mass research goals.
• Aerobic activity: supports general metabolic health.
• Sleep: quality sleep matters because natural GH release is strongly linked with deep sleep.
• Stress management: chronic stress can affect hormonal balance and recovery.
• Fasted timing: some research-style discussions suggest avoiding food around administration to support GH response.

Use the Peptide Calculator

If your vial size, water volume or target amount is different, use the Peptide Hub Australia calculator to work out concentration, mL and syringe units.

Where to Compare CJC-1295 No DAC Suppliers

Peptide Hub Australia does not sell CJC-1295 No DAC or any other peptides. We compare Australian peptide vendors, package audits, pricing and supplier information to help users review the market more clearly.

Frequently Asked Questions

How much BAC water do you add to a 5mg CJC-1295 No DAC vial?

A common educational example is 3.0mL bacteriostatic water added to a 5mg vial, creating a concentration of approximately 1.67mg/mL.

How many units is 100mcg of CJC-1295 No DAC?

If a 5mg vial is mixed with 3.0mL, 100mcg is approximately 6 units on a U-100 insulin syringe.

How many units is 150mcg of CJC-1295 No DAC?

Using the same 5mg in 3.0mL example, 150mcg is approximately 9 units on a U-100 insulin syringe.

How many units is 300mcg of CJC-1295 No DAC?

Using the same 5mg in 3.0mL example, 300mcg is approximately 18 units on a U-100 insulin syringe.

What is the difference between CJC-1295 DAC and No DAC?

The DAC version has a longer activity profile because it binds to albumin. The No DAC version is shorter acting and is commonly discussed for more pulsatile GH release.

Why is bedtime timing commonly discussed?

Bedtime timing is often mentioned because natural growth hormone release is strongly linked with deep sleep and nocturnal GH pulses.

Is this a personal dosing recommendation?

No. This page is an educational reconstitution and measurement guide only. It is not medical advice or a personal protocol.

Related Resources

• Peptide Calculator
• Compare Australian Peptide Vendors
• Compare Peptide Prices
• Package Audits